Search Results - "Wolchok, Jedd D"

Cancer immunotherapy using checkpoint blockade by Ribas, Antoni, Wolchok, Jedd D

“…The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting…”
Get full text

The many faces of the anti-COVID immune response by Vardhana, Santosha A, Wolchok, Jedd D

“…The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a…”
Get full text

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations by Zou, Weiping, Wolchok, Jedd D, Chen, Lieping

“…PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable antitumor responses and long-term remissions in a subset of…”
Get more information

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies by Zappasodi, Roberta, Merghoub, Taha, Wolchok, Jedd D.

“…Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of…”
Get full text

Immune Checkpoint Blockade in Cancer Therapy by Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D

“…Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1…”
Get full text

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways by Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D., Merghoub, Taha

“…The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as…”
Get full text

Immunotherapy of Melanoma: Facts and Hopes by Weiss, Sarah A, Wolchok, Jedd D, Sznol, Mario

“…Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines, and cell…”
Get full text

The future of cancer immunotherapy: microenvironment-targeting combinations by Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.

“…Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary…”
Get full text

Targeting T Cell Co-receptors for Cancer Therapy by Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.

“…Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the…”
Get full text

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy by Callahan, Margaret K., Wolchok, Jedd D.

“…Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in…”
Get full text

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy by Khalil, Danny N., Smith, Eric L., Brentjens, Renier J., Wolchok, Jedd D.

“…Key Points Cancer immunotherapies have the potential to generate robust antitumour responses; this can be achieved through several methods, such as modulatory…”
Get full text

TNF in the era of immune checkpoint inhibitors: friend or foe? by Chen, Allen Y., Wolchok, Jedd D., Bass, Anne R.

“…Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care…”
Get full text

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner by Holmgaard, Rikke B., Zamarin, Dmitriy, Li, Yanyun, Gasmi, Billel, Munn, David H., Allison, James P., Merghoub, Taha, Wolchok, Jedd D.

“…Indoleamine 2,3-dioxygenase (IDO) has been described as a major mechanism of immunosuppression in tumors, though the mechanisms of this are poorly understood…”
Get full text

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma by Schadendorf, Dirk, Hodi, F Stephen, Robert, Caroline, Weber, Jeffrey S, Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M, Wolchok, Jedd D

“…To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of…”
Get full text

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis by Dubin, Krista, Callahan, Margaret K., Ren, Boyu, Khanin, Raya, Viale, Agnes, Ling, Lilan, No, Daniel, Gobourne, Asia, Littmann, Eric, Huttenhower, Curtis, Pamer, Eric G., Wolchok, Jedd D.

“…The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific…”
Get full text

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody by Iwama, Shintaro, De Remigis, Alessandra, Callahan, Margaret K, Slovin, Susan F, Wolchok, Jedd D, Caturegli, Patrizio

“…Hypophysitis is a chronic inflammation of the pituitary gland of unknown (primary forms) or recognizable (secondary forms) etiology, such as the use of…”
Get more information

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade by Benci, Joseph L., Johnson, Lexus R., Choa, Ruth, Xu, Yuanming, Qiu, Jingya, Zhou, Zilu, Xu, Bihui, Ye, Darwin, Nathanson, Katherine L., June, Carl H., Wherry, E. John, Zhang, Nancy R., Ishwaran, Hemant, Hellmann, Matthew D., Wolchok, Jedd D., Kambayashi, Taku, Minn, Andy J.

“…Interferon-gamma (IFNG) augments immune function yet promotes T cell exhaustion through PDL1. How these opposing effects are integrated to impact immune…”
Get full text

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity by Moral, John Alec, Leung, Joanne, Rojas, Luis A., Ruan, Jennifer, Zhao, Julia, Sethna, Zachary, Ramnarain, Anita, Gasmi, Billel, Gururajan, Murali, Redmond, David, Askan, Gokce, Bhanot, Umesh, Elyada, Ela, Park, Youngkyu, Tuveson, David A., Gönen, Mithat, Leach, Steven D., Wolchok, Jedd D., DeMatteo, Ronald P., Merghoub, Taha, Balachandran, Vinod P.

“…Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian tissues 1 , 2 . Although ILC2s are found in cancers of these tissues 3 ,…”
Get full text

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine by Campesato, Luis Felipe, Budhu, Sadna, Tchaicha, Jeremy, Weng, Chien-Huan, Gigoux, Mathieu, Cohen, Ivan Jose, Redmond, David, Mangarin, Levi, Pourpe, Stephane, Liu, Cailian, Zappasodi, Roberta, Zamarin, Dmitriy, Cavanaugh, Jill, Castro, Alfredo C., Manfredi, Mark G., McGovern, Karen, Merghoub, Taha, Wolchok, Jedd D.

“…Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different…”
Get full text

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics by Seymour, Lesley, Prof, Bogaerts, Jan, PhD, Perrone, Andrea, MD, Ford, Robert, MD, Schwartz, Lawrence H, Prof, Mandrekar, Sumithra, Prof, Lin, Nancy U, MD, Litière, Saskia, PhD, Dancey, Janet, Prof, Chen, Alice, MD, Hodi, F Stephen, Prof, Therasse, Patrick, MD, Hoekstra, Otto S, Prof, Shankar, Lalitha K, MD, Wolchok, Jedd D, MD, Ballinger, Marcus, PhD, Caramella, Caroline, MD, de Vries, Elisabeth G E, Prof

“…Summary Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour…”
Get full text